Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCYC Bicycle Therapeutics	$7.85 +0.9%	$7.96	$6.10 ▼ $28.67	$545.62M	1.41	396,220 shs	118,691 shs
BEAM Beam Therapeutics	$20.54 +2.3%	$17.91	$13.53 ▼ $35.25	$2.07B	2.07	1.56 million shs	739,539 shs
CGON CG Oncology	$27.22 +4.4%	$25.96	$14.80 ▼ $40.47	$2.08B	0.86	859,375 shs	310,899 shs
KNSA Kiniksa Pharmaceuticals International	$28.58 +0.6%	$27.80	$17.82 ▼ $30.69	$2.09B	0.05	553,495 shs	117,334 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCYC Bicycle Therapeutics	+1.30%	-2.75%	-3.23%	+5.28%	-66.77%
BEAM Beam Therapeutics	+2.50%	-6.48%	+20.76%	+18.06%	-26.46%
CGON CG Oncology	+4.53%	-3.55%	+2.44%	+26.36%	-30.73%
KNSA Kiniksa Pharmaceuticals International	+1.17%	-1.32%	+0.04%	+40.62%	+27.16%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BCYC Bicycle Therapeutics	3.7459 of 5 stars	4.4	2.0	2.5	4.2	0.6
BEAM Beam Therapeutics	2.2327 of 5 stars	3.5	0.0	3.1	2.5	0.6
CGON CG Oncology	2.5041 of 5 stars	4.5	1.0	2.7	0.8	0.0
KNSA Kiniksa Pharmaceuticals International	3.3416 of 5 stars	3.5	4.0	2.1	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCYC Bicycle Therapeutics	2.70	Moderate Buy	$24.22	208.52% Upside
BEAM Beam Therapeutics	3.00	Buy	$48.75	137.39% Upside
CGON CG Oncology	3.08	Buy	$55.30	103.15% Upside
KNSA Kiniksa Pharmaceuticals International	3.00	Buy	$39.33	37.62% Upside

Current Analyst Ratings Breakdown

Latest BCYC, CGON, KNSA, and BEAM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/17/2025	BCYC Bicycle Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$32.00 ➝ $25.00
7/16/2025	CGON CG Oncology	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$68.00 ➝ $53.00
7/10/2025	CGON CG Oncology	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$40.00
7/9/2025	KNSA Kiniksa Pharmaceuticals International	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$30.00 ➝ $42.00
6/17/2025	CGON CG Oncology	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$52.00 ➝ $56.00
5/19/2025	CGON CG Oncology	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$55.00 ➝ $52.00
5/7/2025	BEAM Beam Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$78.00 ➝ $55.00
5/7/2025	BEAM Beam Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$75.00 ➝ $70.00
5/7/2025	BEAM Beam Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$31.00 ➝ $25.00
5/5/2025	BCYC Bicycle Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Equal Weight ➝ Equal Weight	$15.00 ➝ $17.00
5/2/2025	BCYC Bicycle Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$35.00 ➝ $32.00

(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCYC Bicycle Therapeutics	$35.28M	15.41	N/A	N/A	$11.48 per share	0.68
BEAM Beam Therapeutics	$63.52M	32.51	N/A	N/A	$8.86 per share	2.32
CGON CG Oncology	$662K	3,134.32	N/A	N/A	$9.63 per share	2.83
KNSA Kiniksa Pharmaceuticals International	$423.24M	4.93	N/A	N/A	$6.60 per share	4.33

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCYC Bicycle Therapeutics	-$169.03M	-$3.14	N/A	N/A	N/A	-790.07%	-25.54%	-21.23%	8/5/2025 (Estimated)
BEAM Beam Therapeutics	-$376.74M	-$4.61	N/A	N/A	N/A	-609.24%	-44.24%	-30.97%	8/5/2025 (Estimated)
CGON CG Oncology	-$88.04M	-$1.51	N/A	N/A	N/A	-15,945.17%	-16.71%	-16.24%	8/14/2025 (Estimated)
KNSA Kiniksa Pharmaceuticals International	-$43.19M	-$0.25	N/A	114.33	N/A	-3.52%	-3.83%	-2.98%	7/22/2025 (Estimated)

Latest BCYC, CGON, KNSA, and BEAM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	CGON CG Oncology	-$0.49	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	BCYC Bicycle Therapeutics	-$0.95	N/A	N/A	N/A	$9.43 million	N/A
8/5/2025	Q2 2025	BEAM Beam Therapeutics	-$1.04	N/A	N/A	N/A	$13.29 million	N/A
7/22/2025	Q2 2025	KNSA Kiniksa Pharmaceuticals International	$0.08	N/A	N/A	N/A	N/A	N/A
5/13/2025	Q1 2025	CGON CG Oncology	-$0.36	-$0.45	-$0.09	-$0.45	$0.53 million	$0.05 million
5/6/2025	Q1 2025	BEAM Beam Therapeutics	-$1.11	-$1.24	-$0.13	-$1.24	$14.69 million	$7.47 million
5/1/2025	Q1 2025	BCYC Bicycle Therapeutics	-$0.86	-$0.88	-$0.02	-$0.88	$8.67 million	$9.98 million
4/29/2025	Q1 2025	KNSA Kiniksa Pharmaceuticals International	$0.02	$0.11	+$0.09	$0.11	$128.35 million	$137.79 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCYC Bicycle Therapeutics	N/A	N/A	N/A	N/A	N/A
BEAM Beam Therapeutics	N/A	N/A	N/A	N/A	N/A
CGON CG Oncology	N/A	N/A	N/A	N/A	N/A
KNSA Kiniksa Pharmaceuticals International	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCYC Bicycle Therapeutics	N/A	14.86	14.86
BEAM Beam Therapeutics	N/A	8.81	8.81
CGON CG Oncology	N/A	30.97	30.97
KNSA Kiniksa Pharmaceuticals International	N/A	3.66	3.43

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCYC Bicycle Therapeutics	86.15%
BEAM Beam Therapeutics	99.68%
CGON CG Oncology	26.56%
KNSA Kiniksa Pharmaceuticals International	53.95%

Insider Ownership

Company	Insider Ownership
BCYC Bicycle Therapeutics	22.90%
BEAM Beam Therapeutics	3.50%
CGON CG Oncology	7.40%
KNSA Kiniksa Pharmaceuticals International	53.48%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCYC Bicycle Therapeutics	240	69.25 million	53.40 million	Optionable
BEAM Beam Therapeutics	510	100.56 million	97.04 million	Optionable
CGON CG Oncology	61	76.23 million	70.58 million	Optionable
KNSA Kiniksa Pharmaceuticals International	220	72.97 million	33.95 million	Optionable

BCYC, CGON, KNSA, and BEAM Headlines

Recent News About These Companies

Insider Selling: Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) COO Sells 18,900 Shares of Stock

July 17 at 6:34 AM | insidertrades.com

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) COO Eben Tessari Sells 18,900 Shares

July 16 at 6:47 PM | marketbeat.com

Kiniksa Pharmaceuticals International PLC - Barron's

July 15 at 8:49 AM | barrons.com

Kiniksa Pharmaceuticals International (KNSA) Projected to Post Quarterly Earnings on Tuesday

July 15 at 2:21 AM | marketbeat.com

Rice Hall James & Associates LLC Has $13.87 Million Stock Position in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA)

July 14 at 6:36 AM | marketbeat.com

Wells Fargo & Company Forecasts Strong Price Appreciation for Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock

July 9, 2025 | marketbeat.com

Wealth Enhancement Advisory Services LLC Purchases New Shares in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA)

July 9, 2025 | marketbeat.com

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Upgraded to "Buy" at Wall Street Zen

July 7, 2025 | americanbankingnews.com

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Upgraded at Wall Street Zen

July 6, 2025 | marketbeat.com

Kiniksa Pharmaceuticals: A 7.9 Score and Room for Growth

July 2, 2025 | msn.com

Kiniksa Pharmaceuticals: A 7.9 Score and Room for Growth

July 2, 2025 | msn.com

5 Biotech Stocks to Buy in 2025 Amid Uncertain Macroenvironment

July 2, 2025 | zacks.com

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Given Average Rating of "Buy" by Analysts

July 2, 2025 | marketbeat.com

Peregrine Capital Management LLC Has $6.87 Million Stock Position in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA)

July 1, 2025 | marketbeat.com

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Lowered to "Hold" Rating by Wall Street Zen

June 28, 2025 | marketbeat.com

AMI Asset Management Corp Acquires 26,010 Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA)

June 26, 2025 | marketbeat.com

Kiniksa Pharmaceuticals International PLC - KNSA | Barron's

June 24, 2025 | barrons.com

Kiniksa pharma COO Tessari sells $489k in shares

June 19, 2025 | investing.com

Kiniksa pharma COO Tessari sells $489k in shares

June 19, 2025 | investing.com

Eben Tessari Sells 17,300 Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Stock

June 19, 2025 | insidertrades.com

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Shares Bought by GAMMA Investing LLC

June 19, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCYC, CGON, KNSA, and BEAM Company Descriptions

Bicycle Therapeutics NASDAQ:BCYC

$7.85 +0.07 (+0.91%)

As of 12:50 PM Eastern

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Beam Therapeutics NASDAQ:BEAM

$20.54 +0.47 (+2.32%)

As of 12:50 PM Eastern

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

CG Oncology NASDAQ:CGON

$27.22 +1.14 (+4.38%)

As of 12:50 PM Eastern

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

Kiniksa Pharmaceuticals International NASDAQ:KNSA

$28.58 +0.16 (+0.57%)

As of 12:50 PM Eastern

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time